22 March 2023 - - US-based PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, said that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1 COVIDITY clinical trial.

The trial was conducted at the University of Cape Town Lung Institute in South Africa to assess the safety and immunogenicity of their COVID-19 DNA candidate vaccines, SCOV1 and SCOV2.

The vaccines were exclusively administered using the PharmaJet Tropis and Stratis needle-free precision delivery systems.

The results from the trial were highly encouraging, inducing neutralizing antibody and T cell responses with no safety concerns.

Administration with PharmaJet's devices was well received by study participants.

This new set of human data adds to the growing evidence indicating that this modern needle-free administration technology is an increasingly viable option to enhance plasmid DNA vaccine immune response.

PharmaJet's vision is to enable greater access to life-saving vaccines and pharmaceuticals globally. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health.

PharmaJet Needle-free precision delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use.

The Stratis System has US FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.

The Tropis System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs.

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease.

The company is building a pipeline of innovative products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognize damaged or infected cells.

In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs. The company's unique approach is that its innovative products target modifications of proteins and lipids.

For the vaccines (Moditope and ImmunoBody) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab) or enhances the potency of antibodies and their ability to directly kill tumor cells (AvidiMab).